



PRESS RELEASE

Crucell and DSM Biologics Announce PER.C6[®] Licensing Agreement with UMN Pharma

Leiden/Sittard, The Netherlands, March 9, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6[®] research license agreement with Japanese pharmaceutical company UMN Pharma. This license agreement allows UMN Pharma to use the PER.C6[®] cell line in its 'UMN-03' project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus.

In addition, Crucell and DSM Biologics will provide UMN Pharma with various services including vector construction, clone generation, process development and cGMP manufacturing, through its own facilities in Groningen, The Netherlands and within the PER.C6[®] vendor network.

Under the terms of the agreement, UMN Pharma will pay a signing fee and annual maintenance fees. The additional services will also attract fees. Further financial details are not disclosed.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with: sanofi pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6[®] production technology. The company also licenses its PER.C6[®] technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.

About DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6[®] human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics' FDA-approved facility in Groningen, the Netherlands was established in 1986, and has a strong track record in using a broad range of cell lines (PER.C6[®], CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has



wide-range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6 human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. DSM Biologics is represented by Asahi Glass Co., Ltd. in Japan. For more information, please visit www.dsmbiologics.com.

Crucell's Licensing Program Disclosure Policy

Crucell believes it has a duty to inform investors about every licensing agreement it reaches with third parties – regardless of the significance of current or future revenue or royalties generated by the agreement. Crucell fulfils this duty by issuing a press release that invariably consists of the name of the contract party, the nature of the license and an indication of the relevant technology or therapeutic area. This ensures that every potential investor or interested party can be fully up-to-date with all licensing agreements made by Crucell with third parties. An overview of all Crucell's licensees and partners can be found on the Company's website, including an overview of each relevant product's phase of development.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States.

For further information please contact:

Crucell N.V.

Harry Suykerbuyk
Director Investor Relations and
Corporate Communications
Tel. +31-(0)71-524 8718
h.suykerbuyk@crucell.com

DSM Biologics

Marcel Lubben
Global Licensing Manager
Tel. + 31 (0)46 47 73343
Fax. + 31 (0)46 47 73179
marcel-m.lubben@dsm.com

DSM Pharmaceutical Products

Terry Novak
Chief Marketing Officer
Tel. 973-257-8471
Terry.Novak@dsm.com